Distinct Gut Microbiota Signatures Are Associated with Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease in People with HIVOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated whether gut microbiota composition differs by severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV (PWH). Stool samples underwent 16S rRNA gene sequencing to characterize bacterial genera, and PICRUSt was used to generate functional predictions from the microbiota data. Severe MASLD was defined by the presence of metabolic dysfunction-associated steatohepatitis (MASH), based on cytokeratin-18 levels, and/or significant liver fibrosis, based on liver stiffness measurement. Differential abundance of taxa and predicted functions was analyzed using a generalized linear model with a negative binomial distribution.
Who was studied?
The study prospectively recruited people with HIV who had MASLD, defined by a controlled attenuation parameter (CAP) of 238 dB/m or greater. People with viral hepatitis coinfection or alcohol abuse were excluded from the cohort. Among 34 PWH with MASLD, 18 (53%) met criteria for severe MASLD, while the remainder did not, allowing comparison between these two groups within the same population.
What were the most important findings?
Gut microbiota profiling revealed significant differences in bacterial genera between PWH with severe MASLD and those without severe disease. Notably, enrichment of the Ruminococcus gnavus group was observed in association with severe disease status. These findings indicate that distinct microbial signatures track with the presence of MASH and/or significant fibrosis rather than MASLD alone. The abstract as provided does not specify additional taxa or the full set of predicted functional pathways beyond this enrichment.
What are the greatest implications of this study?
These findings suggest that gut microbiota alterations, particularly enrichment of the Ruminococcus gnavus group, may be linked to more severe liver disease in people with HIV who have MASLD. This raises the possibility that gut microbiota profiling could eventually help identify PWH at higher risk of MASH or significant fibrosis. Because PWH are already a high-risk group for MASLD, understanding microbiome contributions to severity could inform future risk-stratification or microbiome-targeted approaches in this population. Further research is needed to determine whether these microbial signatures are causal or consequential to disease severity.